Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR6LXM)

Drug Name

CAP-232 Drug Info

Synonyms

TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Phase 2a	[1]
Pain	MG30-MG3Z	Phase 2	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 6918265
CAS Number: CAS 147159-51-1
TTD Drug ID: DMR6LXM

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Pyruvate kinase M2 (PKM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TP-1454	DMBTL2M	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pyruvate kinase M2 (PKM)	TT4LOT8	KPYM_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00735332) Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma. U.S. National Institutes of Health.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.